Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity

Philip E. Castle, Tammy Shields, Reinhard Kirnbauer, M. Michele Manos, Robert D. Burk, Andrew G. Glass, David R. Scott, Mark E. Sherman, Mark Schiffman

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Sexual behaviors have been linked to seropositivity for human papillomavirus (HPV) but not with the magnitude of the seroreactivity. Goals: The objective of this analysis was to examine the association of sexual behavior, cervical HPV 16 DNA positivity at enrollment (past) and at diagnosis (current), and other potential determinants with the likelihood and magnitude of HPV 16 seropositivity at diagnosis. Study Design: With use of stored specimens from an incidence case-control study at Kaiser Permanente (Portland, OR), women were tested for seroreactivity to HPV 16 by enzyme-linked immunosorbent assay with virus-like particles at diagnosis and were tested for past and concurrent cervical HPV 16 DNA positivity with MY09/MY11 L1 consensus primer PCR. Questionnaire data were used to ascertain past sexual behavior. Results: Increased lifetime number of sex partners (PTrend < 0.001), past HPV 16 DNA positivity (odds ratio = 6.9; 95% confidence interval = 1.5-31), and a current cytologic diagnosis (PTrend < 0.03) were independently associated with HPV 16 seropositivity. Among the seropositive, only lifetime number of sex partners (PTrend < 0.001) and past HPV 16 DNA positivity (P = 0.003) were independently associated with mean signal strength (optical density) in an age-adjusted analysis. Women negative for past and concurrent HPV 16 DNA had a significant trend of increasing optical densities associated with greater numbers of lifetime partners (PTrend < 0.001). Conversely, the mean signal strength for those women who were ever HPV 16 DNA-positive during the study did not depend on lifetime numbers of sex partners (PTrend = 0.36). Conclusions: HPV 16 seropositivity is a surrogate for past HPV 16 infection. Circulating levels of antibodies to HPV 16 may reflect recent HPV 16 infection or the frequency of past HPV 16 infection.

Original languageEnglish (US)
Pages (from-to)182-187
Number of pages6
JournalSexually Transmitted Diseases
Volume29
Issue number3
StatePublished - 2002

Fingerprint

Papillomavirus Infections
Human papillomavirus 16
Sexual Behavior
DNA
Virion
Case-Control Studies

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)

Cite this

Castle, P. E., Shields, T., Kirnbauer, R., Manos, M. M., Burk, R. D., Glass, A. G., ... Schiffman, M. (2002). Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sexually Transmitted Diseases, 29(3), 182-187.

Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. / Castle, Philip E.; Shields, Tammy; Kirnbauer, Reinhard; Manos, M. Michele; Burk, Robert D.; Glass, Andrew G.; Scott, David R.; Sherman, Mark E.; Schiffman, Mark.

In: Sexually Transmitted Diseases, Vol. 29, No. 3, 2002, p. 182-187.

Research output: Contribution to journalArticle

Castle, PE, Shields, T, Kirnbauer, R, Manos, MM, Burk, RD, Glass, AG, Scott, DR, Sherman, ME & Schiffman, M 2002, 'Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity', Sexually Transmitted Diseases, vol. 29, no. 3, pp. 182-187.
Castle PE, Shields T, Kirnbauer R, Manos MM, Burk RD, Glass AG et al. Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sexually Transmitted Diseases. 2002;29(3):182-187.
Castle, Philip E. ; Shields, Tammy ; Kirnbauer, Reinhard ; Manos, M. Michele ; Burk, Robert D. ; Glass, Andrew G. ; Scott, David R. ; Sherman, Mark E. ; Schiffman, Mark. / Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. In: Sexually Transmitted Diseases. 2002 ; Vol. 29, No. 3. pp. 182-187.
@article{21b4de0df5824e32a780c7e88ad4d31d,
title = "Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity",
abstract = "Background: Sexual behaviors have been linked to seropositivity for human papillomavirus (HPV) but not with the magnitude of the seroreactivity. Goals: The objective of this analysis was to examine the association of sexual behavior, cervical HPV 16 DNA positivity at enrollment (past) and at diagnosis (current), and other potential determinants with the likelihood and magnitude of HPV 16 seropositivity at diagnosis. Study Design: With use of stored specimens from an incidence case-control study at Kaiser Permanente (Portland, OR), women were tested for seroreactivity to HPV 16 by enzyme-linked immunosorbent assay with virus-like particles at diagnosis and were tested for past and concurrent cervical HPV 16 DNA positivity with MY09/MY11 L1 consensus primer PCR. Questionnaire data were used to ascertain past sexual behavior. Results: Increased lifetime number of sex partners (PTrend < 0.001), past HPV 16 DNA positivity (odds ratio = 6.9; 95{\%} confidence interval = 1.5-31), and a current cytologic diagnosis (PTrend < 0.03) were independently associated with HPV 16 seropositivity. Among the seropositive, only lifetime number of sex partners (PTrend < 0.001) and past HPV 16 DNA positivity (P = 0.003) were independently associated with mean signal strength (optical density) in an age-adjusted analysis. Women negative for past and concurrent HPV 16 DNA had a significant trend of increasing optical densities associated with greater numbers of lifetime partners (PTrend < 0.001). Conversely, the mean signal strength for those women who were ever HPV 16 DNA-positive during the study did not depend on lifetime numbers of sex partners (PTrend = 0.36). Conclusions: HPV 16 seropositivity is a surrogate for past HPV 16 infection. Circulating levels of antibodies to HPV 16 may reflect recent HPV 16 infection or the frequency of past HPV 16 infection.",
author = "Castle, {Philip E.} and Tammy Shields and Reinhard Kirnbauer and Manos, {M. Michele} and Burk, {Robert D.} and Glass, {Andrew G.} and Scott, {David R.} and Sherman, {Mark E.} and Mark Schiffman",
year = "2002",
language = "English (US)",
volume = "29",
pages = "182--187",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity

AU - Castle, Philip E.

AU - Shields, Tammy

AU - Kirnbauer, Reinhard

AU - Manos, M. Michele

AU - Burk, Robert D.

AU - Glass, Andrew G.

AU - Scott, David R.

AU - Sherman, Mark E.

AU - Schiffman, Mark

PY - 2002

Y1 - 2002

N2 - Background: Sexual behaviors have been linked to seropositivity for human papillomavirus (HPV) but not with the magnitude of the seroreactivity. Goals: The objective of this analysis was to examine the association of sexual behavior, cervical HPV 16 DNA positivity at enrollment (past) and at diagnosis (current), and other potential determinants with the likelihood and magnitude of HPV 16 seropositivity at diagnosis. Study Design: With use of stored specimens from an incidence case-control study at Kaiser Permanente (Portland, OR), women were tested for seroreactivity to HPV 16 by enzyme-linked immunosorbent assay with virus-like particles at diagnosis and were tested for past and concurrent cervical HPV 16 DNA positivity with MY09/MY11 L1 consensus primer PCR. Questionnaire data were used to ascertain past sexual behavior. Results: Increased lifetime number of sex partners (PTrend < 0.001), past HPV 16 DNA positivity (odds ratio = 6.9; 95% confidence interval = 1.5-31), and a current cytologic diagnosis (PTrend < 0.03) were independently associated with HPV 16 seropositivity. Among the seropositive, only lifetime number of sex partners (PTrend < 0.001) and past HPV 16 DNA positivity (P = 0.003) were independently associated with mean signal strength (optical density) in an age-adjusted analysis. Women negative for past and concurrent HPV 16 DNA had a significant trend of increasing optical densities associated with greater numbers of lifetime partners (PTrend < 0.001). Conversely, the mean signal strength for those women who were ever HPV 16 DNA-positive during the study did not depend on lifetime numbers of sex partners (PTrend = 0.36). Conclusions: HPV 16 seropositivity is a surrogate for past HPV 16 infection. Circulating levels of antibodies to HPV 16 may reflect recent HPV 16 infection or the frequency of past HPV 16 infection.

AB - Background: Sexual behaviors have been linked to seropositivity for human papillomavirus (HPV) but not with the magnitude of the seroreactivity. Goals: The objective of this analysis was to examine the association of sexual behavior, cervical HPV 16 DNA positivity at enrollment (past) and at diagnosis (current), and other potential determinants with the likelihood and magnitude of HPV 16 seropositivity at diagnosis. Study Design: With use of stored specimens from an incidence case-control study at Kaiser Permanente (Portland, OR), women were tested for seroreactivity to HPV 16 by enzyme-linked immunosorbent assay with virus-like particles at diagnosis and were tested for past and concurrent cervical HPV 16 DNA positivity with MY09/MY11 L1 consensus primer PCR. Questionnaire data were used to ascertain past sexual behavior. Results: Increased lifetime number of sex partners (PTrend < 0.001), past HPV 16 DNA positivity (odds ratio = 6.9; 95% confidence interval = 1.5-31), and a current cytologic diagnosis (PTrend < 0.03) were independently associated with HPV 16 seropositivity. Among the seropositive, only lifetime number of sex partners (PTrend < 0.001) and past HPV 16 DNA positivity (P = 0.003) were independently associated with mean signal strength (optical density) in an age-adjusted analysis. Women negative for past and concurrent HPV 16 DNA had a significant trend of increasing optical densities associated with greater numbers of lifetime partners (PTrend < 0.001). Conversely, the mean signal strength for those women who were ever HPV 16 DNA-positive during the study did not depend on lifetime numbers of sex partners (PTrend = 0.36). Conclusions: HPV 16 seropositivity is a surrogate for past HPV 16 infection. Circulating levels of antibodies to HPV 16 may reflect recent HPV 16 infection or the frequency of past HPV 16 infection.

UR - http://www.scopus.com/inward/record.url?scp=0036123531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036123531&partnerID=8YFLogxK

M3 - Article

C2 - 11875380

AN - SCOPUS:0036123531

VL - 29

SP - 182

EP - 187

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 3

ER -